Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer

Clinical Trial Title

Phase III trial of docetaxel vs. docetaxel and radium-223 for metastatic castration-resistant prostate cancer (mCRPC).

Clinical Trial Protocol Description:

This is an open-labeled, randomized, phase III study of docetaxel versus docetaxel in combination with radium-223 in subjects with mCRPC.

Clinical Trial Eligibility Criteria:

In order to participate you must have:

  • Have histological or cytological proof of prostate cancer.
  • Have received external beam radiotherapy within the 4 weeks prior to randomization.
  • Have received four or more systemic anticancer regimens for mCRPC.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Dian Wang, MD, PhD

Contact Information

Rush Cancer Center Clinical Trials Office